Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

483
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
483
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Coronary Artery Disease V: Surgical Management01:27

Coronary Artery Disease V: Surgical Management

3
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
3
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

581
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
581
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

2
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
2
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

3
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
3

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Long-term mavacamten exposure reduces force and sarcomere density in a hiPSC model of hypertrophic cardiomyopathy.

Cardiovascular research·2026
Same author

Treatment effects in contemporary cardiovascular pharmacotherapy: determinants and interpretation.

European heart journal. Cardiovascular pharmacotherapy·2026
Same author

Obesity and Pharmacokinetic Variability: Implications for Cardiovascular Therapeutics.

European cardiology·2026
Same author

C1qa□ muscularis macrophages maintain enteric synaptic homeostasis to regulate gastrointestinal motility.

bioRxiv : the preprint server for biology·2026
Same author

Antidotes for Anticoagulation Reversal.

The New England journal of medicine·2026
Same author

A TRIP-nano killer silencing the pain pacemakers.

The Journal of physiology·2026

相关实验视频

Updated: Jun 11, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

801

提卡格勒和他类药物:危险的联系?

Bianca Rocca1,2, Elisabetta Bigagli3, Elisabetta Cerbai4

  • 1Department of Safety and Bioethics, Catholic University, Largo F. Vito 1, Rome, Italy.

Cardiovascular drugs and therapy
|September 30, 2024
PubMed
概括

提卡格雷勒可以抑制乳腺癌抵抗蛋白 (BCRP),增加他类药物水平和狂犬病溶解的风险. 治疗提卡格勒勒和他类药物的心血管患者需要对这种药物相互作用进行仔细监测.

关键词:
细胞染色体P450的使用.药物相互作用 药物相互作用拉布多溶解 (Rhabdomyolysis) 是一种类他类药物是一种药物.刺或刺,或者刺.运输商 运输商 运输商

更多相关视频

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

4.8K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K

相关实验视频

Last Updated: Jun 11, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

801
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

4.8K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 心血管医学 心血管医学
  • 药物相互作用 药物相互作用

背景情况:

  • 多药在心血管患者中很常见,增加了药物相互作用 (DDI) 的风险.
  • 在这个人群中,抗血栓性药物和他类药物经常被共同处方.
  • 涉及他类药物的DDI可能会导致严重的不良事件,如狂肌分裂.

研究的目的:

  • 为了研究蒂卡格勒罗和他类药物之间的DDI机制.
  • 为了确定乳腺癌抗性蛋白 (BCRP) 在提卡格雷勒-他类药物相互作用中的作用.
  • 为了评估与此DDI相关的腹肌溶解的潜在风险.

主要方法:

  • 在体外研究评估BCRP抑制由tcagrelor.
  • 评估药物度的药理动力学试验.
  • 在形药物建模中验证相互作用机制.

主要成果:

  • 提卡格勒罗被确定为BCRP载体的抑制剂.
  • 这种由提卡格勒的抑制会增加作为BCRP基质的他类药物的度.
  • 观察性研究表明,用提卡格雷勒和某些类他类药物增加了拉布地质溶解的风险.

结论:

  • 蒂卡格勒勒对BCRP的抑制是一种已验证的机制,有助于与他类药物的DDI.
  • 这种相互作用可能会导致他类药物的度增加和更高的狂犬病溶解风险.
  • 当与敏感的他类药物同时开药时,需要谨慎和进一步调查.